Clinical Trial Update: Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement [Phase 1]

View source ↗

Summary

Phase 1 study assessing the effects of the dopamine D3 receptor antagonist GSK598809 on food reward and reinforcement in people with substance use disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Substance Use Disorder

Drugs mentioned

• GSK598809 (GSK598809)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Substance Dependence | Phase 1 | Status: COMPLETED